Interest of Two Digital Devices for the Diagnosis of Neurocognitive Disorders in Elderly People With Cognitive Symptoms.

Sponsor
RIVAGES (Other)
Overall Status
Recruiting
CT.gov ID
NCT06032611
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (Other), Université d'Évry (Other), Hôpital Charles Foix (Other)
150
2
1
12
75
6.2

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare conventional clinical data collected as part of usual practice with data collected by the two digital tools to help diagnose major and minor neurocognitive disorders in elderly people consulting a memory center for cognitive complaints. The main question[s] it aims to answer are:

  • Is it possible to create a classification between the different intensities of cognitive impairment?

  • Is it possible to create a diagnostic tool consistent with the reference diagnosis? Participants will be asked to complete a series of cognitive and fine motor tasks, and will be given questionnaires on their lifestyle and medical history. They will be asked to wear a connected watch for 1 week.

There is no comparison group.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: COGNUM_ALZVR
N/A

Detailed Description

Alzheimer's disease, which leads to dementia, has an insidious onset and a slow, gradual progression. After a completely asymptomatic phase that can last several years (prodromal stage of the disease), the first signs consist of a moderate deterioration in performance in one or more cognitive domains, such as memory, attention, planning or other cognitive faculties. Clinically, this is referred to as mild neurocognitive impairment (MCI) due to Alzheimer's disease. The progression is towards a major neurocognitive disorder, in which cognitive dysfunction progressively increases, and the patient becomes dependent for activities of daily living. Early detection of the disease, and specifically of this mild neurocognitive disorder, is crucial for a window of intervention prior to dementia. The investigators propose to evaluate a tablet version of a manual dexterity test that the investigators have already been able to test, in combination with assessments already established in the clinic and physiological data collected by a connected watch, to help diagnose neurocognitive disorders by confronting them with the clinical data that are the reference.

The investigators propose this multicenter observational study with a diagnostic aim. The study will involve 150 elderly people consulting one of the two participating memory centers. Three groups will be formed: 50 people with no cognitive dysfunction, 50 with a mild neurocognitive disorder, and 50 with a major neurocognitive disorder linked to Alzheimer's disease. These groups will be formed on the basis of the reference diagnosis established by the memory consultation teams, and the results of the patient's neuropsychological and medical assessments. The investigators will retrieve data from the medical record to classify cognitive status.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Interest of Two Digital Devices for the Diagnosis of Neurocognitive Disorders in Elderly People With Cognitive Symptoms.
Actual Study Start Date :
Apr 17, 2023
Anticipated Primary Completion Date :
Apr 17, 2024
Anticipated Study Completion Date :
Apr 17, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Participants will complete a number of cognitive and fine motor tests on a touch-sensitive tablet. They will also be asked to complete a questionnaire on their habits and medical history. They will also be asked to wear a smartwatch for 7 days.

Diagnostic Test: COGNUM_ALZVR
Participants will complete a battery of tests/quizzes: cognitive tests medical questionnaire lifestyle/fragility questionnaire digital clock test fine motor skills tests They will also wear a connected watch for 7 days.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity, specificity, accuracy [through study completion, an average of 1 year]

    Sensitivity, specificity, accuracy of the classification proposed by the algorithm in relation to the reference diagnosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • elderly people consulting the memory center ;

  • people with one of three documented cognitive diagnoses:

  • major neurocognitive impairment due to Alzheimer's disease according to DSM-5 criteria,

  • mild neurocognitive impairment

  • no documented cognitive dysfunction after assessment at the memory center,

  • willingness to participate in the study and sign the consent form.

Exclusion Criteria:
  • persons with an illness affecting the hand (orthopedic, neurological, Parkinson's disease) that prevents them from using a touch-sensitive tablet;

  • persons with other illnesses that may be responsible for loss of cognitive function (cerebrovascular disease, other neurological illnesses, psychiatric illnesses);

  • persons benefiting from legal protection.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Privé Gériatrique Les Magnolias Ballainvilliers Essonne France 91160
2 Hôpital Charles Foix Ivry-sur-Seine Val De Marne France 94200

Sponsors and Collaborators

  • RIVAGES
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Université d'Évry
  • Hôpital Charles Foix

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
RIVAGES
ClinicalTrials.gov Identifier:
NCT06032611
Other Study ID Numbers:
  • COGNUM
  • IDRCB2022-A00609-34
First Posted:
Sep 13, 2023
Last Update Posted:
Sep 13, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by RIVAGES
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2023